Share Twitter LinkedIn Facebook Email Paul M. Barr MD Associate Professor of Medicine at Wilmot Cancer Institute provides his opinion on ibrutinib in 1st line chronic lymphocytic leukemia (CLL). Advertisement
CAR T-cell Therapy in CLL (chronic lymphocytic leukemia): Navigating the Landscape and Looking Ahead with Catherine Coombs, MD Chronic Lymphocytic Leukemia 3 Mins Read
Nitin Jain, MD Challenging case involving advanced B-cell lymphoblastic leukemia (BLL) from the CAR-T and Bispecifics Conference [2024] Chronic Lymphocytic Leukemia 3 Mins Read
Positive Outcomes & Tolerability Sonrotoclax + Zanubrutinib in TN-CLL/SLL – ASH 2023 Updates Chronic Lymphocytic Leukemia 1 Min Read
